Can you provide the average price target for BIOTE CORP -A stock?
11 analysts have analysed BTMD and the average price target is 4.94 USD. This implies a price increase of 274.26% is expected in the next year compared to the current price of 1.32.
NASDAQ:BTMD • US0906831039
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIOTE CORP -A (BTMD).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-12 | TD Cowen | Maintains | Buy -> Buy |
| 2026-03-12 | B. Riley Securities | Maintains | Neutral -> Neutral |
| 2025-08-07 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2025-03-13 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-12-16 | Craig-Hallum | Initiate | Buy |
| 2024-03-13 | Roth MKM | Reiterate | Buy -> Buy |
| 2024-02-20 | B. Riley Securities | Initiate | Buy |
| 2024-02-01 | Jefferies | Initiate | Buy |
| 2024-01-18 | Roth MKM | Maintains | Buy -> Buy |
| 2024-01-18 | Truist Securities | Maintains | Buy -> Buy |
| 2023-08-15 | TD Cowen | Maintains | Outperform -> Outperform |
| 2023-08-14 | Roth MKM | Reiterate | Buy -> Buy |
| 2023-03-30 | Roth MKM | Maintains | Buy |
| 2022-09-27 | Truist Securities | Initiate | Buy |
| 2022-06-24 | Cowen & Co. | Initiate | Outperform |
| 2022-06-23 | Roth Capital | Initiate | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 185.36M 12.34% | 197.191M 6.38% | 192.219M -2.52% | 196.12M 2.03% | 209.02M 6.58% | 224.4M 7.36% | 282.54M 25.91% | 298.86M 5.78% | |
| EBITDA YoY % growth | 31.651M 154.01% | 35.185M 11.17% | 39.221M 11.47% | 53.902M 37.43% | 58.967M 9.40% | 70.38M 19.35% | 75.48M 7.25% | 79.56M 5.41% | |
| EBIT YoY % growth | 28.657M 147.13% | 31.611M 10.31% | 35.551M 12.46% | 26.63M -25.09% | 32.56M 22.27% | 53.04M 62.90% | 56.1M 5.77% | 59.16M 5.45% | |
| Operating Margin | 15.46% | 16.03% | 18.50% | 13.58% | 15.58% | 23.64% | 19.86% | 19.80% | |
| EPS YoY % growth | -0.22 -112.61% | 0.22 200.00% | 0.83 277.27% | 0.26 -69.28% | 0.29 12.00% | 1.16 307.14% | 1.24 7.02% | 1.32 5.74% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 0.05 -86.91% | 0.07 -60.33% | 0.08 -62.91% | 0.10 70.00% |
| Revenue Q2Q % growth | 46.943M -4.18% | 50.606M 3.57% | 51.908M 8.24% | 53.411M 15.09% |
| EBITDA Q2Q % growth | 8.766M -16.89% | 13.177M 5.15% | 14.035M 27.75% | 15.09M 43.73% |
| EBIT Q2Q % growth | 5.553M -42.69% | 7.673M -28.72% | 9.371M 13.35% | 11.358M 66.32% |
All data in USD
11 analysts have analysed BTMD and the average price target is 4.94 USD. This implies a price increase of 274.26% is expected in the next year compared to the current price of 1.32.
BIOTE CORP -A (BTMD) will report earnings on 2026-05-05.
The consensus EPS estimate for the next earnings of BIOTE CORP -A (BTMD) is 0.05 USD and the consensus revenue estimate is 46.94M USD.
The expected long term growth rate for BIOTE CORP -A (BTMD) is 4.7%.